Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncotelic Therapeutics, Inc. (OTLC) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, S-1, S-1/A, 8-K, and related documents. As a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and rare pediatric indications, Oncotelic uses these filings to report on its financial condition, capital-raising activities, joint ventures, and material agreements.
Recent Form 8-K filings detail unregistered sales of equity securities through unit offerings of notes and warrants to accredited investors, including conversion features into Oncotelic common stock or shares of consolidated minority-owned subsidiary EdgePoint AI, Inc. They also describe amendments to independent contractor and restricted stock agreements tied to market capitalization milestones, as well as corporate presentations and press releases, such as the announcement of open access to the PDAOAI platform and its TGF-β literature corpus.
Registration statements on Form S-1 and Form S-1/A outline resale arrangements with Mast Hill Fund, LP under a Note Purchase Agreement and an Equity Purchase Agreement. These documents specify the number of shares registered, warrant coverage, and the company’s status as a smaller reporting company. Together with periodic reports, they give investors insight into equity structures, potential dilution, and ongoing financing strategies.
Additional filings, such as Form 12b-25 (NT 10-Q), explain timing extensions for quarterly reports and provide context on anticipated changes in results of operations. By reviewing these filings, users can understand how Oncotelic structures its financings, manages joint venture interests like GMP Bio and Sapu Nano, and discloses risks and forward-looking statements associated with its oncology, RNA therapeutic, nanomedicine, and AI-driven platforms. Stock Titan’s interface, combined with AI-powered summaries, helps interpret complex disclosures, highlight key terms in offerings and agreements, and surface material events that may be relevant to OTLC shareholders and analysts.
Oncotelic Therapeutics (OTLC) furnished an investor presentation given by CEO Dr. Vuong Trieu at LD Micro in San Diego on October 21, 2025. The presentation, filed as Exhibit 99.1, includes forward-looking statements covering areas such as JV plans (including a potential IPO), clinical development timing and data reporting, regulatory approvals, the company’s nanoparticle platform, a planned DAO-based company, pet and animal health initiatives, and token-related registrations and tradability.
The materials are furnished under Item 8.01 and are not deemed “filed,” which limits their incorporation into other SEC filings.